Viral infections remain a major cause of morbidity and mortality in solid organ transplant (SOT) recipients, haematopoietic transplant (HSCT) recipients and in other settings of immunocompromise. Adoptive transfer of virus-specific T cells (VST) represents a promising therapeutic strategy; however, access to timely, scalable treatments remains a significant clinical challenge. At QIMR Berghofer we have developed a multi-virus T cell therapy (MVT) program. I will provide an update on ongoing clinical trials using MVT in SOT and HSCT patients, and on our compassionate program that provides T cells to patients in Australia and New Zealand.